Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients

Kidney International

Volumn 63, Issue 3, 2003, Pages 1086-1093

  Kaneko, Yoshikatsu ^a,b   Miyazaki, Shigeru ^a   Hirasawa, Yoshihei ^a   Gejyo, Fumitake ^a   Suzuki, Masashi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Shinrakuen Hospital   (Japan)

Author keywords

Anemia; Chronic hemodialysis; Erythropoietin; Parenteral iron; Randomized controlled trial; Serum ferritin

Indexed keywords

FERRIC HYDROXIDE; FERRITIN; HEMOGLOBIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; ERYTHROCYTE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HUMAN TISSUE; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; SUPPLEMENTATION;

EID: 0037340047     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00826.x     Document Type: Article

References (35)

1. ESCHBACH JW, EGRIE JC, DOWNING MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
2. ESCHBACH JW, KELLY MR, HALEY NR, et al: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
3. ESCHBACH JW, ABDULHADI MH, BROWNE JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
4. BESARAB A, FLAHARTY KK, ERSLEV AJ, et al: Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 2:1405-1416, 1992
5. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
6. HÖRL WH, CAVILL I, MACDOUGALL IC, et al: How to diagnose and correct iron deficiency during r-huEPO therapy - A consensus report. Nephrol Dial Transplant 11:246-250, 1996
7. MACDOUGALL IC: Optimal iron management in patients receiving erythropoietin therapy. Semin Dial 11:10-13, 1998
8. NATIONAL KIDNEY FOUNDATION - DIALYSIS OUTCOMES QUALITY INITIATIVE: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37(Suppl 1):S182-S238, 2001
9. BESARAB A, FRINAK S, YEE J: An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10:2029-2043, 1999
10. TARNG D, HUANG T, CHEN TW, YANG W: Erythropoietin hypo-responsiveness: From iron deficiency to iron overload. Kidney Int 55(Suppl 69):S107-S118, 1999
11. SUNDER-PLASSMANN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
12. LINDSAY RM, BURTON JA, KING P, et al: The measurement of dialyzer blood loss. Clin Nephrol 1:24-28, 1973
13. FISHBANE S, FREI GL, MAESAKA J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
14. SEPANDJ F, JINDAL K, WEST M, HIRSCH D: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996
15. TAYLOR JE, PEAT N, PORTER C, MORGAN AG: Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996
16. MACDOUGALL IC, TUCKER B, THOMPSON J, et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996
17. MACDOUGALL IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 3:620-625, 1994
18. FISHBANE S, KOWALSKI EA, IMBRIANO LJ, MAESAKA JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7:2654-2657, 1996
19. BESARAB A, KAISER JW, FRINAK S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34:21-28, 1999
20. BESARAB A, AMIN N, AHSAN M, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538, 2000
21. FISHBANE S, LYNN RI: The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25:426-432, 1995
22. BOVY C, TSOBO C, CRAPANZANO L, et al: Factors determining the percentage of hypochromic red brood cells in hemodialysis patients. Kidney Int 56:1113-1119, 1999
23. BRAUN J, HAMMERSCHMIDT M, SCHREIBER M, et al: Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Nephrol Dial Transplant 11:492-497, 1996
24. BRAUN J: Erythrocyte zinc protoporphyrin. Kidney Int 55(Suppl 69):S57-S60, 1999
25. AHLUWALIA N, SKIKNE BS, SAVIN V, CHONKO A: Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 30:532-541, 1997
26. BRUGNARA C: Reticulocyte hemoglobin content (CHr): Early indicator of iron deficiency and response to therapy. Blood 83:3100-3101, 1994
27. SCHAEFER RM, SCHAEFER L: Hypochromic red blood cells and reticulocytes. Kidney Int 55(Suppl 69):S44-S48, 1999
28. TESSITORE N, SOLERO GP, LIPPI G, et al: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16:1416-1423, 2001
29. FISHBANE S, GALGANO C, LANGLEY RC, JR, et al: Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52:217-222, 1997
30. MITTMAN N, SREEDHARA R, MUSHNICK R, et al: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 30:912-922, 1997
31. CULLEN P, SÖFFKER J, HÖPFL M, et al: Hypochromic red cells and reticulocyte haemoglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 14:659-665, 1999
32. FISHBANE S, SHAPIRO W, DUTKA P, et al: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60:2406-2411, 2001
33. HOEN B, KESSLER M, HESTIN D, MAYEUX D: Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 10:377-381, 1995
34. EUROPEAN BEST PRACTICE GUIDELINES FOR THE MANAGEMENT OF ANEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE: Guideline 8: Administration of supplemental iron. Nephrol Dial Transplant 14(Suppl 5):17-18, 1999
35. AUERBACH M, WINCHESTER J, WAHAB A, et al: A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 31:81-86, 1998